DK1043025T3 - Behandling af nyrecellekarcinom - Google Patents

Behandling af nyrecellekarcinom

Info

Publication number
DK1043025T3
DK1043025T3 DK00107100T DK00107100T DK1043025T3 DK 1043025 T3 DK1043025 T3 DK 1043025T3 DK 00107100 T DK00107100 T DK 00107100T DK 00107100 T DK00107100 T DK 00107100T DK 1043025 T3 DK1043025 T3 DK 1043025T3
Authority
DK
Denmark
Prior art keywords
treatment
cell carcinoma
renal cell
renal
carcinoma
Prior art date
Application number
DK00107100T
Other languages
English (en)
Inventor
Esther Helen Rose
Mary Ellen Rybak
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of DK1043025T3 publication Critical patent/DK1043025T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
DK00107100T 1999-04-08 2000-04-06 Behandling af nyrecellekarcinom DK1043025T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28835999A 1999-04-08 1999-04-08

Publications (1)

Publication Number Publication Date
DK1043025T3 true DK1043025T3 (da) 2005-07-04

Family

ID=23106761

Family Applications (2)

Application Number Title Priority Date Filing Date
DK00107100T DK1043025T3 (da) 1999-04-08 2000-04-06 Behandling af nyrecellekarcinom
DK05002952T DK1535623T3 (da) 1999-04-08 2000-04-06 Nyrecelle-carcinom behandling

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK05002952T DK1535623T3 (da) 1999-04-08 2000-04-06 Nyrecelle-carcinom behandling

Country Status (24)

Country Link
EP (2) EP1535623B1 (da)
JP (2) JP3712914B2 (da)
CN (1) CN1367702A (da)
AR (1) AR029160A1 (da)
AT (2) ATE419002T1 (da)
AU (2) AU777406B2 (da)
BR (1) BR0009644A (da)
CA (1) CA2303752A1 (da)
CO (1) CO5170412A1 (da)
CY (1) CY1108919T1 (da)
DE (2) DE60020442T2 (da)
DK (2) DK1043025T3 (da)
ES (2) ES2319777T3 (da)
HK (2) HK1032533A1 (da)
HU (1) HU230271B1 (da)
MX (1) MXPA00003401A (da)
MY (1) MY155221A (da)
NO (1) NO328983B1 (da)
NZ (1) NZ514629A (da)
PE (1) PE20010026A1 (da)
PT (2) PT1535623E (da)
TW (2) TW200526243A (da)
WO (1) WO2000061174A2 (da)
ZA (1) ZA200108169B (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ514629A (en) * 1999-04-08 2004-02-27 Schering Corp PEGylated interferon-alpha administered at about 4.5- 9.0 micrograms/kg/week as a renal cell carcinoma treatment
CA2648077A1 (en) * 2006-03-31 2007-11-08 Schering Corporation Parenteral low dose type 1 interferons for bladder cancer
TW200901989A (en) * 2007-04-10 2009-01-16 Wyeth Corp Anti-tumor activity of CCI-779 in papillary renal cell cancer
US8053430B2 (en) 2008-10-06 2011-11-08 Haraldsson Boerje Treatment of renal cell carcinoma
JP2013523726A (ja) 2010-04-01 2013-06-17 オンコレナ エービー 腎細胞癌の改良された治療
CN103463623B (zh) * 2013-09-03 2015-09-09 长春海伯尔生物技术有限责任公司 一种聚乙二醇干扰素注射液及其制备方法
AU2018274216A1 (en) 2017-05-24 2019-12-12 Novartis Ag Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
WO2024186735A1 (en) * 2023-03-03 2024-09-12 Memorial Sloan-Kettering Cancer Center Methods and compositions for the treatment of cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766582A (en) * 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
ID28470A (id) * 1998-03-26 2001-05-24 Schering Corp Formulasi-formulasi untuk perlindungan terhadap konjugasi polietilen glikol-interferon alfa
NZ514629A (en) * 1999-04-08 2004-02-27 Schering Corp PEGylated interferon-alpha administered at about 4.5- 9.0 micrograms/kg/week as a renal cell carcinoma treatment

Also Published As

Publication number Publication date
EP1043025A2 (en) 2000-10-11
DE60041291D1 (de) 2009-02-12
WO2000061174A3 (en) 2001-01-25
JP3712914B2 (ja) 2005-11-02
HU230271B1 (hu) 2015-11-30
AU777406B2 (en) 2004-10-14
BR0009644A (pt) 2002-01-08
HK1075417A1 (en) 2005-12-16
CO5170412A1 (es) 2002-06-27
HUP0200781A2 (en) 2002-08-28
AU2004242454B2 (en) 2007-02-15
EP1043025B1 (en) 2005-06-01
PT1535623E (pt) 2009-03-19
AU4204400A (en) 2000-11-14
EP1535623A1 (en) 2005-06-01
DE60020442D1 (de) 2005-07-07
CN1367702A (zh) 2002-09-04
TW200526243A (en) 2005-08-16
PT1043025E (pt) 2005-09-30
JP2000319196A (ja) 2000-11-21
JP4721488B2 (ja) 2011-07-13
EP1535623B1 (en) 2008-12-31
NO20014851L (no) 2001-12-07
ES2319777T3 (es) 2009-05-12
DE60020442T2 (de) 2006-05-04
ATE296638T1 (de) 2005-06-15
AU2004242454A1 (en) 2005-01-20
MXPA00003401A (es) 2002-03-08
ES2239953T3 (es) 2005-10-16
MY155221A (en) 2015-09-30
AR029160A1 (es) 2003-06-18
DK1535623T3 (da) 2009-04-27
EP1043025A3 (en) 2000-12-20
TWI310314B (en) 2009-06-01
NO328983B1 (no) 2010-07-05
NO20014851D0 (no) 2001-10-05
WO2000061174A2 (en) 2000-10-19
JP2001288110A (ja) 2001-10-16
CA2303752A1 (en) 2000-10-08
CY1108919T1 (el) 2014-07-02
NZ514629A (en) 2004-02-27
ZA200108169B (en) 2003-01-06
PE20010026A1 (es) 2001-02-05
HK1032533A1 (en) 2001-07-27
ATE419002T1 (de) 2009-01-15
HUP0200781A3 (en) 2002-09-30

Similar Documents

Publication Publication Date Title
DE60003693D1 (de) Kanalstromfilter
DE60037170D1 (de) Leitschaufel
DE10084903T1 (de) Polyetherpolyurethan
DE60021217D1 (de) Ostomievorrichtung
ATE319461T1 (de) Simethicon enthaltendes abführmittel
DK1210085T3 (da) Farmaceutiske oplösninger af levosimendan
DK1176964T3 (da) Brug af ET743 til behandling af cancer
DE60024711D1 (de) Leitschaufel
DE60037233D1 (de) Hämofiltrationsvorrichtung
HK1075417A1 (en) Renal cell carcinoma treatment
DE60024400D1 (de) Empfangsgerät
FI991476A0 (fi) Alipäästösuodatin
DK1155050T3 (da) Fremstilling af polyolefin
DE60007475D1 (de) Filter
NO20013596L (no) Slambehandling
DE60022086D1 (de) Wasserbehandlung
DK1088010T3 (da) Fremstilling af polyolefiner
DE60037071D1 (de) Magentischer Energiefilter
DE59911042D1 (de) Planarfilter
DE50002979D1 (de) Kabelkanal
DK199901559A (da) Stomi/brok-bandage
PT1020132E (pt) Aba de puxar destacavel
DE60039142D1 (de) Energiefilter
FI113576B (fi) Suodatin
DK1227795T3 (da) Lipidkompleks af alkycycliner